Researchers at the Perelman School of Medicine at the University of Pennsylvania have made significant progress in the fight against the H5N1 avian influenza virus, which is currently affecting birds and cattle in the United States.
Their development of an experimental mRNA vaccine has shown high effectiveness in preventing severe illness and death in animal models, according to a recent publication in Nature Communications.
The team, led by Scott Hensley, Ph.D., a professor of Microbiology, and in collaboration with Drew Weissman, MD, Ph.D., a noted pioneer in mRNA vaccine technology and Nobel Prize winner, has utilized the flexibility of mRNA technology to rapidly respond to potential pandemic threats.
This technology, which gained global attention during the COVID-19 pandemic, enables the creation of vaccines within hours of sequencing a new viral strain.
Traditional influenza vaccines, which are primarily produced using fertilized chicken eggs, face significant delays due to the time required for the virus to adapt to and replicate within the eggs.
This process can take up to six months, often resulting in vaccines becoming available only after the peak of a pandemic.
In contrast, mRNA vaccines can be quickly adjusted to target specific viral strains without the need for egg-based production, offering a significant advantage in pandemic responsiveness.
The focus of the Penn team’s current research is a subtype of the H5N1 virus that, while rare in humans, poses a considerable risk due to its potential to evolve into a pandemic form.
The new mRNA vaccine not only elicited a robust immune response in mice and ferrets, characterized by strong antibody and T cell activities, but also showed that these animals maintained high levels of antibodies for up to a year post-vaccination.
More importantly, in experiments where vaccinated animals were later exposed to the H5N1 virus, they were able to clear the virus more quickly and exhibited fewer symptoms compared to unvaccinated controls. Remarkably, all vaccinated animals survived the infection, while those unvaccinated did not.
The researchers also compared the immune response elicited by the mRNA vaccine to that induced by a traditional egg-based vaccine.
Both vaccines generated strong antibody responses, indicating that the mRNA vaccine was just as effective as the conventional approach, even in animals that had previous exposures to seasonal flu viruses.
This study not only underscores the potential of mRNA vaccines to address rapidly evolving viral threats but also highlights their critical role in managing diseases with pandemic potential.
The quick adaptability and effectiveness of mRNA vaccines, as demonstrated by this research, suggest a promising future for combating not just influenza but other emerging infectious diseases.
The Penn team plans to continue exploring the capabilities of mRNA technology, aiming to enhance global preparedness against viral pandemics.
If you care about medicine, please read studies that vitamin D could help lower the risk of autoimmune diseases, and drug for inflammation may stop spread of cancer.
For more information about medicine, please see recent studies about which drug can harm your liver most, and results showing this drug can give your immune system a double boost against cancer.
The research findings can be found in Nature Communications.
Copyright © 2024 Knowridge Science Report. All rights reserved.
